Impact of clinical trial participation on the survival of patients with newly diagnosed advanced-stage ovarian cancer.

Objective: Clinical trials provide access to novel treatment strategies, which may offer survival benefits to ovarian cancer patients. We sought to determine if participation in any clinical trial is associated with a survival benefit in patients with newly diagnosed advanced-stage ovarian cancer. Methods: We retrospectively investigated the patients who treated for newly diagnosed advanced-stage ovarian cancer at Yonsei Cancer Hospital between 2019 and 2021. This study included 202 patients with stage III-IV, 82 patients who participated in clinical trials and 120 participants receiving standard of care therapy (SOC). Results: The median follow-up duration was 31.5 months. Disease recurrence occurred in 123 (60.9%) patients and 45 (22.3%) patients died. Among the patients in both groups, there were no significant differences in age, histologic type, stage, median cancer antigen 125 level, comorbidities, and BRCA 1/2 status. There were also no differences in the incorporation of hyperthermic intraperitoneal chemotherapy, neoadjuvant chemotherapy, residual disease after cytoreductive surgery. The patients involved in clinical trials were associated with significantly improvement in progression-free survival (PFS) (31.4 vs. 19.2 months; hazard ratio=0.67; 95% confidence interval=0.46-0.97; p=0.034) compared to SOC. There was no difference in overall survival between 2 groups (p=0.164). Conclusion: Clinical trial participation was associated with improved PFS in patients with newly diagnosed advanced-stage ovarian cancer. Clinical trial participation is considered to be beneficial to patients with newly diagnosed advanced-stage ovarian cancer. [ABSTRACT FROM AUTHOR]